NICE’s final draft guidance states that Lumykras (sotorasib) should not be routinely commissioned on the NHS in England and Wales because of limitations in the clinical evidence and uncertainty in the economic model, including its high cost-effectiveness estimates compared to what NICE considers acceptable.
Lumykras will no longer be covered by the Cancer Drugs Fund (CDF) after the current managed access period ends, which effectively discourages future public reimbursement for the drug in the UK unless new evidence or pricing changes sway the decision.
The decision has been met with criticism from clinicians and Amgen, who argue that it leaves patients with KRAS G12C‑positive non‑small‑cell lung cancer without targeted therapy options despite the drug’s established international use and licensing in the UK.
Sources:
NICE aims to cut funding for Amgen lung cancer drug Lumykras
Sotorasib for previously treated KRAS G12C mutation- ...
Bypassing NICE: NHS England Deals Enable Early Access in High ...
UK: Lumykras first drug to come through ILAP and receive positive ...
[PDF] Sotorasib for previously treated KRAS G12C mutation-positive ...
Amgen, NHS strike deal to expand Lumykras access in UK as watchdog weighs its merits
sotorasib (Lumykras®) - All Wales Therapeutics and Toxicology ...
NHS lung cancer patients in England get early access to ...
Amgen's Lumykras recommended by NICE for NSCLC